fluoromisonidazole
Small moleculeexperimentalImaging agent
18F-FMISO or fluoromisonidazole is a radiopharmaceutical used for PET imaging of hypoxia. It consists of a 2-nitroimidazole molecule labelled with the positron-emitter fluorine-18. — Wikipedia
Clinical trial activity
36 trials · 40 clinical orgs · 0 marketing orgs
Phase 1
13
Phase 2
15
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 1994 (NCT00038038)
Timeline
Indications
Studied for
- Brain Neoplasms · Phase 2
- Breast Neoplasms · Phase 2
- Carcinoma, Hepatocellular · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Colorectal Neoplasms · Phase 2
- Esophageal Neoplasms · Phase 1
- Glioblastoma · Phase 2
- Glioma · Phase 2
- Gliosarcoma · Phase 2
- Head and Neck Neoplasms · Phase 1/Phase 2
- Liver Cirrhosis · Phase 1
- Liver Neoplasms · Phase 2
- Lung Neoplasms · Phase 2
- Melanoma · Phase 2
- Nasopharyngeal Carcinoma · Phase 2/Phase 3
- Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 2
- Prostatic Neoplasms · Phase 2
- Sarcoma · Phase 2
- Skin Neoplasms · Phase 2
- Small Cell Lung Carcinoma · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Early Phase 1
- Triple Negative Breast Neoplasms · Early Phase 1
- Uterine Cervical Neoplasms · Phase 2
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
Loading structure…
SMILES
O=[N+]([O-])c1nccn1CC(O)C[18F]- Mol. weight
- 188.15 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Imaging
- 18-fluorine
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaFMISO ↗
- ChEMBLCHEMBL2068841 ↗
- ChEMBLCHEMBL2037002 ↗
Also known as
- 1-(2-nitro-1-imidazolyl)-3-fluoro-2-propanol
- 18f-fluoromisonidazole
- 18f-fluoromisonidazole
- 18f-fluoromisonidazole
- 18f fmiso
- 18f fmiso
- 18f-fmiso
- 18f-fmiso
- 18f-fmiso
- 18-f-miso
- 18f miso
- 18f miso
- 18f-miso
- 18f-miso
- 1-fluoro-2-hydroxypropyl-2-nitroimidazole
- 1-fluoromisonidazole
- (f-18) fluoromisonidazole
- f-18-fluoromisonidazole
- f-18-fluoromisonidazole
- fluoromisonidazole
- fluoromisonidazole, 18f-labeled
- fluoromisonidazole, tritium-labeled
- fluoronormethoxymisonidazole
- fmiso
- fmiso
- fmiso
- f-miso
- ro 07-0741
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05996432 | Early Phase 1 (Phase 1) | May 17, 2023 | National Institutes of Health (NIH), Vanderbilt University |
| NCT04861077 | Early Phase 1 (Phase 1) | Oct 2, 2022 | University of Alabama, Birmingham |
| NCT05250895 | Early Phase 1 (Phase 1) | Apr 28, 2022 | Emory University, National Cancer Institute (NCI) |
| NCT04846309 | Phase 1 | Aug 12, 2021 | University of Utah |
| NCT04309552 | Phase 1 | Feb 1, 2021 | Cornell University, William Rhodes Center for Glioblastoma |
| NCT04332588 | Phase 1 | Aug 31, 2020 | University of Alabama, Birmingham |
| NCT03730077 | Phase 1 | Feb 1, 2019 | University of Pennsylvania |
| NCT03649880 | Phase 2 | Oct 1, 2018 | National Cancer Institute (NCI), OHSU Knight Cancer Institute, Oregon Health and Science University |
| NCT03573986 | Phase 1 | Apr 18, 2018 | University of Pennsylvania |
| NCT03303469 | Phase 2 | Oct 30, 2017 | University of Alabama, Birmingham |
| NCT02498613 | Phase 2 | Apr 26, 2016 | AstraZeneca, National Cancer Institute (NCI), Yale University |
| NCT02695628 | Phase 1 | Mar 1, 2016 | National Cancer Institute (NCI), Stanford University |
| NCT02471313 | Phase 2 | May 20, 2015 | National Institutes of Health (NIH) |
| NCT02061007 | Phase 2 | Oct 1, 2014 | University of South Florida |
| NCT02076152 | N/A | Feb 1, 2014 | Harvard University, National Cancer Institute (NCI) |
| NCT02016872 | N/A | Dec 16, 2013 | Cornell University, National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT01967927 | Early Phase 1 (Phase 1) | Dec 1, 2013 | Hoosier Cancer Research Network |
| NCT02157246 | N/A | Oct 31, 2013 | University of Oxford |
| NCT01868906 | Phase 2 | Jun 1, 2013 | Dr. Negrin University Hospital, Fundación DISA, Canary Islands, Spain, Grupo de Investigación Clínica en Oncología Radioterapia, Mario Negri Institute, RSbiomed, Universidad Carlos III Madrid, University of Texas at Houston |
| NCT02841332 | N/A | May 1, 2013 | University of Toulouse |
Showing 20 of 36 trials
Page 1 / 2
Organizations
Research & Development (40)
40 organizations
Page 1 / 2